Connection

RADEK SKODA to Mice

This is a "connection" page, showing publications RADEK SKODA has written about Mice.
Connection Strength

1.129
  1. Loss of Socs2 improves molecular responses to IFNa in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F. Leukemia. 2025 Apr; 39(4):876-887.
    View in: PubMed
    Score: 0.070
  2. Loss of Dnmt3a increases self-renewal and resistance to pegIFN-a in JAK2-V617F-positive myeloproliferative neoplasms. Blood. 2024 06 13; 143(24):2490-2503.
    View in: PubMed
    Score: 0.066
  3. The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN. Blood Adv. 2024 05 14; 8(9):2312-2325.
    View in: PubMed
    Score: 0.066
  4. IL-1? promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells. Blood Adv. 2024 03 12; 8(5):1234-1249.
    View in: PubMed
    Score: 0.065
  5. Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms. Blood. 2023 04 27; 141(17):2127-2140.
    View in: PubMed
    Score: 0.061
  6. Inhibition of interleukin-1? reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm. Nat Commun. 2022 09 13; 13(1):5346.
    View in: PubMed
    Score: 0.059
  7. JAK2-V617F and interferon-a induce megakaryocyte-biased stem cells characterized by decreased long-term functionality. Blood. 2021 04 22; 137(16):2139-2151.
    View in: PubMed
    Score: 0.053
  8. Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021 Mar; 165(1):26-33.
    View in: PubMed
    Score: 0.052
  9. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. Blood. 2019 11 21; 134(21):1832-1846.
    View in: PubMed
    Score: 0.048
  10. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. J Exp Med. 2016 07 25; 213(8):1479-96.
    View in: PubMed
    Score: 0.038
  11. JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis. Blood. 2016 08 11; 128(6):839-51.
    View in: PubMed
    Score: 0.038
  12. Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN. Blood. 2015 Mar 26; 125(13):2131-40.
    View in: PubMed
    Score: 0.034
  13. Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. J Exp Med. 2014 Oct 20; 211(11):2213-30.
    View in: PubMed
    Score: 0.034
  14. Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs. Blood. 2014 Jun 19; 123(25):3943-50.
    View in: PubMed
    Score: 0.033
  15. Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia. Haematologica. 2014 Apr; 99(4):e52-4.
    View in: PubMed
    Score: 0.032
  16. Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood. 2013 Feb 14; 121(7):1188-99.
    View in: PubMed
    Score: 0.030
  17. Thrombocytosis. Hematology Am Soc Hematol Educ Program. 2009; 159-67.
    View in: PubMed
    Score: 0.023
  18. Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood. 2009 Feb 19; 113(8):1768-77.
    View in: PubMed
    Score: 0.022
  19. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008 Apr 15; 111(8):3931-40.
    View in: PubMed
    Score: 0.021
  20. Normal erythropoiesis but severe polyposis and bleeding anemia in Smad4-deficient mice. Blood. 2007 Oct 15; 110(8):3049-55.
    View in: PubMed
    Score: 0.020
  21. Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood. 2007 Feb 15; 109(4):1503-6.
    View in: PubMed
    Score: 0.019
  22. Nuclear and cytosolic fractions of SOX2 synergize as transcriptional and translational co-regulators of cell fate. Cell Rep. 2024 10 22; 43(10):114807.
    View in: PubMed
    Score: 0.017
  23. A truncated isoform of c-Mpl with an essential C-terminal peptide targets the full-length receptor for degradation. J Biol Chem. 2004 Aug 27; 279(35):36397-404.
    View in: PubMed
    Score: 0.017
  24. A 2-kb c-mpl promoter fragment is sufficient to direct expression to the megakaryocytic lineage and sites of embryonic hematopoiesis in transgenic mice. Blood. 2002 Aug 01; 100(3):1072-4.
    View in: PubMed
    Score: 0.015
  25. Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation. Cancer Discov. 2019 09; 9(9):1228-1247.
    View in: PubMed
    Score: 0.012
  26. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest. 2019 03 04; 129(4):1596-1611.
    View in: PubMed
    Score: 0.011
  27. Permissive role of thrombopoietin and granulocyte colony-stimulating factor receptors in hematopoietic cell fate decisions in vivo. Proc Natl Acad Sci U S A. 1999 Jan 19; 96(2):698-702.
    View in: PubMed
    Score: 0.011
  28. The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. Haematologica. 2019 04; 104(4):710-716.
    View in: PubMed
    Score: 0.011
  29. HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis. Nat Commun. 2018 04 12; 9(1):1431.
    View in: PubMed
    Score: 0.011
  30. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood. 2017 12 28; 130(26):2848-2859.
    View in: PubMed
    Score: 0.010
  31. The leptin receptor activates janus kinase 2 and signals for proliferation in a factor-dependent cell line. Mol Endocrinol. 1997 Apr; 11(4):393-9.
    View in: PubMed
    Score: 0.010
  32. Defective STAT signaling by the leptin receptor in diabetic mice. Proc Natl Acad Sci U S A. 1996 Jun 25; 93(13):6231-5.
    View in: PubMed
    Score: 0.010
  33. Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency. Blood. 2016 06 23; 127(25):3253-9.
    View in: PubMed
    Score: 0.009
  34. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood. 1996 Jan 15; 87(2):567-73.
    View in: PubMed
    Score: 0.009
  35. Expression of c-MYC under the control of GATA-1 regulatory sequences causes erythroleukemia in transgenic mice. J Exp Med. 1995 May 01; 181(5):1603-13.
    View in: PubMed
    Score: 0.009
  36. Estrogen signaling selectively induces apoptosis of hematopoietic progenitors and myeloid neoplasms without harming steady-state hematopoiesis. Cell Stem Cell. 2014 Dec 04; 15(6):791-804.
    View in: PubMed
    Score: 0.009
  37. Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging. J Thromb Haemost. 2014 Dec; 12(12):2120-30.
    View in: PubMed
    Score: 0.008
  38. Haemorrhagic and thrombotic diatheses in mouse models with thrombocytosis. Thromb Haemost. 2015 Feb; 113(2):414-25.
    View in: PubMed
    Score: 0.008
  39. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature. 2014 Aug 07; 512(7512):78-81.
    View in: PubMed
    Score: 0.008
  40. Murine c-mpl: a member of the hematopoietic growth factor receptor superfamily that transduces a proliferative signal. EMBO J. 1993 Jul; 12(7):2645-53.
    View in: PubMed
    Score: 0.008
  41. The DEAH-box helicase RHAU is an essential gene and critical for mouse hematopoiesis. Blood. 2012 May 03; 119(18):4291-300.
    View in: PubMed
    Score: 0.007
  42. Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation. Blood. 2011 Sep 29; 118(13):3670-9.
    View in: PubMed
    Score: 0.007
  43. SCL-mediated regulation of the cell-cycle regulator p21 is critical for murine megakaryopoiesis. Blood. 2011 Jul 21; 118(3):723-35.
    View in: PubMed
    Score: 0.007
  44. Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. Blood. 2010 Jul 29; 116(4):661-70.
    View in: PubMed
    Score: 0.006
  45. Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. J Exp Med. 2007 Dec 24; 204(13):3103-11.
    View in: PubMed
    Score: 0.005
  46. Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion. Blood. 2007 Nov 01; 110(9):3183-91.
    View in: PubMed
    Score: 0.005
  47. Expression of LIF in transgenic mice results in altered thymic epithelium and apparent interconversion of thymic and lymph node morphologies. EMBO J. 1994 Mar 15; 13(6):1375-85.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.